Thu, Oct 2, 2014, 2:27 AM EDT - U.S. Markets open in 7 hrs 3 mins

Recent

% | $
Quotes you view appear here for quick access.

Medivation, Inc. (MDVN) Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    I might get back in if price is between $92-$95. I am loyal to Xtandi and had all my portfolio in it for 6 months, now it's mostly Gilead. Xtandi has great potential especially if they can get into breast cancer too. It will definitely take over Zytiga's $1.7 Billion market, better results, no Prednisone, no diet restrictions.

    My main worry is what happens when JNJ accelerates their ARN-509 "Son Of Medivation" trials and bring it to market by 2016. MDVN is unfortunately a one trick pony, a great one though.

    Sentiment: Hold

  • in 93 countries. Many drugs have priced themselves out of the market and Obamacare is broke.

  • put Medivation back in court with the inventor of Xtandi, The University of California. JNJ owns the superior version knowing its Zytiga is going generic next year.

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    Funny because MDVN is rated higher than GS or JPM by analysts. STRONG BUY MDVN while we have down day.

  • Reply to

    Riceen

    by riceenseenmstoknowethefuture Sep 25, 2014 8:21 AM

    Agree. Where does one subscribe or find this famous Riceen letter?

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    GS has not credibility. It's all about employee performance. Those kids struggle to score high.

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    me too !!

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    On that occasion, they lowered their price target on ITMN to $49 ...also on "valuation". Since Goldman was one of the banks advising ITMN on the sale, many took this as an indication that the buyout offer would be around 50 and the stock, which had been advancing, actually fell back for a couple of sessions. Ten days later, Roche offered $74 a share for ITMN. In the future, I'm going to buy any biotech Goldman downgrades on "valuation".

  • However he raises Sales estimates Substantially and sees great and strong sales trends....Sorry, but this looks more like an upgrade and reiteration, but trying to temper enthusiasm. Stock has come back 3 points and should end UP for day which will really cause Shorts to wet their pants

    Sentiment: Strong Buy

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    Goldman Sachs downgraded Medivation (NASDAQ: MDVN) from Buy to Neutral with a price target of $110.00 (unchanged). The downgrade is tied to valuation.

    Analyst Navdeep Singh said, "We are downgrading MDVN to Neutral from Buy as we believe the current stock price fairly values prostate and breast cancer opportunities for Xtandi. Although early signals of Xtandi’s launch in pre-chemo prostate cancer are strong, focus has shifted to phase 2 data of Xtandi in androgen receptor positive (AR+) triple negative breast cancer (TNBC) in Q4. Post our research of Xtandi’s potential in breast cancer, we are increasing our Xtandi peak sales estimate by $1.5bn to $8bn (from $6.5bn, all prostate cancer). Despite this increase, our new 12-month price target is $110, which only yields 12% upside. Since adding MDVN to the Buy list on May 6, 2013, the stock is +85% vs. the NBI +55%."

    For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

    Shares of Medivation closed at $98.59 yesterday.





    Goldman Sachs downgraded Medivation (NASDAQ: MDVN) from Buy to Neutral with a price target of $110.00 (unchanged). The downgrade is tied to valuation.

    Analyst Navdeep Singh said, "We are downgrading MDVN to Neutral from Buy as we believe the current stock price fairly values prostate and breast cancer opportunities for Xtandi. Although early signals of Xtandi’s launch in pre-chemo prostate cancer are strong, focus has shifted to phase 2 data of Xtandi in androgen receptor positive (AR+) triple negative breast cancer (TNBC) in Q4. Post our research of Xtandi’s potential in breast cancer, we are increasing our Xtandi peak sales estimate by $1.5bn to $8bn (from $6.5bn, all prostate cancer). Despite this increase, our new 12-month price target is $110, which only yields 12% upside. Since adding MDVN to the Buy list on May 6, 2013, the stock is +85% vs. the NBI +55%."

    For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

    Shares of Medivation closed at $98.59 yesterday.





    Goldman Sachs downgraded Medivation (NASDAQ: MDVN) from Buy to Neutral with a price target of $110.00 (unchanged). The downgrade is tied to valuation.

    Analyst Navdeep Singh said, "We are downgrading MDVN to Neutral from Buy as we believe the current stock price fairly values prostate and breast cancer opportunities for Xtandi. Although early signals of Xtandi’s launch in pre-chemo prostate cancer are strong, focus has shifted to phase 2 data of Xtandi in androgen receptor positive (AR+) triple negative breast cancer (TNBC) in Q4. Post our research of Xtandi’s potential in breast cancer, we are increasing our Xtandi peak sales estimate by $1.5bn to $8bn (from $6.5bn, all prostate cancer). Despite this increase, our new 12-month price target is $110, which only yields 12% upside. Since adding MDVN to the Buy list on May 6, 2013, the stock is +85% vs. the NBI +55%."

    For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

    Shares of Medivation closed at $98.59 yesterday.

  • On Seeking Alpha....
    I believe that there is additional upside to Medivation in the following months, and I am initiating Medivation with a buy and a base case price target of $122.
    article:
    2517655-medivation-significant-upside-potential

  • Medivation: Significant Upside Potential
    Sep. 24, 2014 10:30 AM ET | About: Medivation, Inc. (MDVN)

    Disclosure: The author has no positions in any stocks mentioned, but may initiate a long position in MDVN over the next 72 hours. (More...)
    Summary

    Medivation stands to benefit from robust sales of Xtandi in the following years.
    Expanded indication for Xtandi creates an opportunity for blockbuster potential.
    I am initiating Medivation with a buy rating and a base case $122 price target.
    Downside should be limited and welcomed as a buying opportunity.

    Medivation (NASDAQ:MDVN) has been among the top performing biotech stocks since bottoming in late April 2014. The company is benefiting from strong sales of its only drug Xtandi, as revenue grew significantly since the drug's launch in August 2012. The recent FDA approval for an expanded label for Xtandi puts Medivation in a much better position going forward, as it opens up the way for the drug's blockbuster status. Analysts are projecting peak sales at $2.7 billion as opposed to the expected $640 million in revenue for 2014. And that is not the end of Xtandi's growth potential, as the company is working on for different uses for Xtandi, including breast cancer. The expansion beyond prostate cancer could lead to another significant growth stage for Medivation in the coming years. I believe that there is additional upside to Medivation in the following months, and I am initiating Medivation with a buy and a base case price target of $122.

    Sentiment: Buy

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    I had MDVN average $60, sold all at $92(way too soon I know). Thinking of getting back in slowly. I need to change my Yahoo name.

    Sentiment: Hold

  • In probably the worst prediction I've ever seen GS put a $68 price target on Gilead in April saying Solvadi was over hyped. It currently on pace for $12B in sales and stock approaching $110. They are notoriously bad in biotech over there.

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    IMHO, this is just profit taking to take advantage of buy out frenzy. but MDVN could also be taken for the ride. it has been also named as a buyout candidate.

    I think this is a great sleeper candidate.

    Sentiment: Strong Buy

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    Let's not forget the downgrade to neutral on Intermune days before Roche takeout last month.

    Sentiment: Strong Buy

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    tks for that little chunk of history. I have held GILD for 3 yrs, and saw all the idiots make stupid upgrades/downgrades, move PTs, make really low rev fcsts, etc. Many times I was tempted to sell, but I held on.

    I doubt MDVN will be a 5 bagger from here in 5 yrs, but i don't doubt it will be a 5 bagger from the 55 it saw back in May or so, in 3 yrs from that time, ie, I expect 200+ in 2 yrs or less.

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    GS removes it from their Americas Buy List, cuts to neutral from buy, and raises their PT from 90 to 110.

    More wall st gibberish, what it really means, imo, is that GS wants to buy more at lower prices.

  • Reply to

    MDVN Downgraded this morning

    by xtandiinvestor Sep 24, 2014 9:13 AM

    careful switching side now..

    Sentiment: Sell

MDVN
100.35+1.48(+1.50%)Oct 1 4:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.